EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access

A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents

Jan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Caroline E Roe, Jonathan M Irish, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan F Madanat, Joshua F Zeidner und 11 weitere

Annals of Hematology · 2024-01 · 103 (1) · 105-116

DOI: 10.1007/s00277-023-05552-4 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Annals of Hematology, online erschienen am 01.12.2023. Verfasst von Jan Philipp Bewersdorf und 22 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA. jan.bewersd…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with myelodysplastic syndromes/neoplasms (MDS) or acute myeloid leukemia (AML) with hypomethylating agent failure have a poor prognosis. Myeloid-derived suppressor cells (MDSCs) can contribute to MDS progression and mediate resistance to anti-PD1 therapy. As histone deacetylase inhibitors (HDACi) decrease MDSCs in preclinical models, we conducted an investigator-initiated, NCI-Cancer Therapy Evaluation Program-sponsored, multicenter, dose escalation, and expansion phase Ib trial (NCT02936752) of the HDACi entinostat and the anti-PD1 antibody pembrolizumab. Twenty-eight patients (25 MDS and 3 AML) were enrolled. During dose escalation (n=13 patients), there was one dose-limiting toxicity (DLT) on dose level (DL) 1 (G5 pneumonia/bronchoalveolar hemorrhage) and two DLTs at DL 2 (G3 pharyngeal mucositis and G3 anorexia). Per the 3 + 3 dose escalation design, DL 1 (entinostat 8 mg PO days 1 and 15 + pembrolizumab 200 mg IV day 1 every 21 days) was expanded and another 15 patients were enrolled. Hematologic adverse events (AEs) were common. The most common non-hematologic ≥G3 AEs were infection (32%), hypoxia/respiratory failure (11%), and dyspnea (11%). There were no protocol-defined responses among the 28 patients enrolled. Two patients achieved a marrow complete remission (mCR). Using a systems immunology approach with mass cytometry and machine learning analysis, mCR patients had increased classical monocytes and macrophages but there was no significant change of MDSCs. In conclusion, combining entinostat with pembrolizumab in patients with advanced MDS and AML was associated with limited clinical efficacy and substantial toxicity. Absence of an effect on MDSCs could be a potential explanation for the limited efficacy of this combination. ClinicalTrial.gov Identifier: NCT02936752.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteHumansHistone Deacetylase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesPyridinesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

AMLEntinostatMDSMyeloid-derived suppressor cellsPembrolizumab

Substanzen

Histone Deacetylase InhibitorsentinostatBenzamidesPyridinespembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA. jan.bewersdorf@yale.edu.
  • Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. jan.bewersdorf@yale.edu.
  • Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.
  • Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.
  • Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Bewersdorf, J. P., Shallis, R. M., Sharon, E., Park, S., Ramaswamy, R., Roe, C. E., Irish, J. M., Caldwell, A., Wei, W., Yacoub, A., Madanat, Y. F., Zeidner, J. F., Altman, J. K., Odenike, O., Yerrabothala, S., Kovacsovics, T., Podoltsev, N. A., Halene, S., Little, R. F., …, & Zeidan, A. M. (2024). A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Annals of Hematology, 103(1), 105-116. https://doi.org/10.1007/s00277-023-05552-4

Vancouver

Bewersdorf JP, Shallis RM, Sharon E, Park S, Ramaswamy R, Roe CE, et al. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Annals of Hematology. 2024;103(1):105-116. doi:10.1007/s00277-023-05552-4

BibTeX
@article{Bewersdorf2024,
  author = {Bewersdorf, Jan Philipp and Shallis, Rory M and Sharon, Elad and Park, Silvia and Ramaswamy, Rahul and Roe, Caroline E and Irish, Jonathan M and Caldwell, Anne and Wei, Wei and Yacoub, Abdulraheem and Madanat, Yazan F and Zeidner, Joshua F and Altman, Jessica K and Odenike, Olatoyosi and Yerrabothala, Swaroopa and Kovacsovics, Tibor and Podoltsev, Nikolai A and Halene, Stephanie and Little, Richard F and Piekarz, Richard and Gore, Steven D and Kim, Tae Kon and Zeidan, Amer M},
  title = {A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents},
  journal = {Annals of Hematology},
  year = {2024},
  volume = {103},
  number = {1},
  pages = {105--116},
  doi = {10.1007/s00277-023-05552-4}
}
Kostenlos starten →